Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Terminal ballistics of kinase inhibitors: there are no magic bullets.

Literature DB >> 17088586

Terminal ballistics of kinase inhibitors: there are no magic bullets.

Michael L Maitland, Mark J Ratain.

Abstract

Mesh：

Substances：

Year: 2006 PMID： 17088586 DOI： 10.7326/0003-4819-145-9-200611070-00015

Source DB: PubMed Journal: Ann Intern Med ISSN： 0003-4819 Impact factor: 25.391

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.

Authors: Xinan Yang; Yong Huang; Matthew Crowson; Jianrong Li; Michael L Maitland; Yves A Lussier
Journal: J Biomed Inform Date: 2010-05-01 Impact factor: 6.317

Review 2. New trial designs and potential therapies for pulmonary artery hypertension.

Authors: Mardi Gomberg-Maitland; Todd M Bull; Rajeev Saggar; Robyn J Barst; Amany Elgazayerly; Thomas R Fleming; Friedrich Grimminger; Maurizio Rainisio; Duncan J Stewart; Norman Stockbridge; Carlo Ventura; Ardeschir H Ghofrani; Lewis J Rubin
Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094

3. Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.

Authors: Philipp Ivanyi; Thomas Fuehner; Meike Adam; Christian Eichelberg; Edwin Herrmann; Axel Stuart Merseburger; Arnold Ganser; Viktor Grünwald
Journal: Med Oncol Date: 2014-08-15 Impact factor: 3.064

Review 4. Bioengineering approaches to study multidrug resistance in tumor cells.

Authors: Brian Fallica; Guy Makin; Muhammad H Zaman
Journal: Integr Biol (Camb) Date: 2011-03-08 Impact factor: 2.192

5. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

Authors: L K Martin; X Li; B Kleiber; E C Ellison; M Bloomston; M Zalupski; T S Bekaii-Saab
Journal: Ann Oncol Date: 2012-07-05 Impact factor: 32.976

6. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors: M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal: Clin Pharmacol Ther Date: 2009-12-09 Impact factor: 6.875

Terminal ballistics of kinase inhibitors: there are no magic bullets.

1. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.

Review 2. New trial designs and potential therapies for pulmonary artery hypertension.

3. Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.

Review 4. Bioengineering approaches to study multidrug resistance in tumor cells.

5. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

6. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

7. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Review 8. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

9. Endocrine sequelae of cancer and cancer treatments.

10. Advances in cancer therapeutics.